TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $700.35M |
| Gross Profit (TTM) | $581.67M |
| EBITDA | $149.58M |
| Operating Margin | 17.00% |
| Return on Equity | 112.60% |
| Return on Assets | 8.55% |
| Revenue/Share (TTM) | $4.87 |
| Book Value | $4.11 |
| Price-to-Book | 14.64 |
| Price-to-Sales (TTM) | 11.99 |
| EV/Revenue | 12.53 |
| EV/EBITDA | 58.43 |
| Quarterly Earnings Growth (YoY) | 300.00% |
| Quarterly Revenue Growth (YoY) | 69.60% |
| Shares Outstanding | $153.08M |
| Float | $135.10M |
| % Insiders | 7.47% |
| % Institutions | 70.30% |
Volatility is currently expanding
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S.
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TGTX and any ticker you trade — then tracks every position and per-strategy win rate.
